Wipfli Financial Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wipfli Financial Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$11K	Buy	+268	New	+$13.8K	﹤0.01%	1812

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wipfli Financial Advisors's RARE Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q3 2022: 268 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #1812 among its holdings.

232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

Wipfli Financial Advisors held 268 shares of Ultragenyx Pharmaceutical worth $11K as of Q3 2022.
Ultragenyx Pharmaceutical was a new Wipfli Financial Advisors position in Q3 2022.
Ultragenyx Pharmaceutical made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1812 holding.
232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.